The information on this page comes from the UK Activity Report.
Click here for further details

Shire Pharmaceuticals Shire Pharmaceuticals is to acquire Transkaryotic Therapies, the US biotechnology company that produces drugs for genetic disorders, for £839m. 25-Apr-2005 Shire Pharmaceuticals is to sell its vaccines division to ID Biomedical of Canada for £66m, and Shire will loan about £60m to ID to fund the development of new products. 21-Apr-2004 Shire Pharmaceuticals is looking to spend up to £550m on a large acquisition, as part of a strategy to reduce its reliance on its hyperactivity drug. 12-Mar-2004 Shire Pharmaceuticals is considering plans to close its early-stage drugs research unit, sell off its vaccines business and seek large acquisitions in the US. 01-Aug-2003 Shire Pharmaceuticals has awarded a $18m contract to AMEC to build a global vaccines research centre at its site in Laval, Canada. 17-Apr-2003 Shire Pharmaceuticals has raised £45m from the sale of its four remaining over-the-counter products to Purdue Pharma. 31-Dec-2002 Shire Pharmaceuticals is to acquire Atlantic Pharmaceutical Services, the US-based pharmaceuticals manufacturer with 100 staff in Maryland, from Niro for £11m. 16-Sep-2002 Skyepharma has raised £15m from the sale of the European distribution rights of the Solaraze skin treatment to Shire Pharmaceuticals, and has also announced a £25m investment from Kowa of Japan. 14-May-2002 Shire Pharmaceuticals has raised £280m from an issue of convertible bonds, in order to fund the acquisition of speciality pharmaceutical products and support its expansion into Japan and Europe. 16-Aug-2001 Shire is planning to cut research costs and make annual savings of £22m following the acquisition of BioChem of Canada, and has also announced an intention to move into the Japanese pharmaceuticals market. 26-Jan-2001 Shire Pharmaceuticals is to acquire BioChem Pharma of Canada for £2.7bn, in order to broaden its portfolio of speciality pharmaceutical products. 12-Dec-2000 Shire has opened an operating subsidiary in Spain, as part of a strategy to develop a global pharmaceuticals business. 08-Jun-2000 Shire Pharmaceuticals is acquiring the French, Italian and German subsidiaries of Fuisz Technologies of the US for £24m, as part of a strategy to build up a global drug development business. 25-Oct-1999 Shire Pharmaceuticals is planning to make a significant acquisition in continental Europe by the end of next year. 20-Oct-1999 Shire Pharmaceuticals is to acquire Roberts Pharmaceutical of the US for £570m, and is now looking at ways to increase sales in continental Europe. 27-Jul-1999 Shire Pharmaceuticals is said to have been negotiating a merger with Medeva, but talks have stalled due to a disagreement over price. 15-Jul-1999 Shire Pharmaceuticals is considering plans to spend up to £800m on a major acquisition in Europe. 12-May-1999 Production of Shire Pharmaceuticals' Arenol hyperactivity drug could be halted for up to 10 months following an explosion at a US factory. 07-Aug-1998 Shire Pharmaceuticals has announced encouraging early results from trials of its galantamine treatment for Alzheimer's disease, indicating that it helps to slow memory loss. 20-Jul-1998 Shire Pharmaceuticals is to re-acquire the worldwide rights to Carbatol, the anticonvulsant, from Elan Corp for £15m. 27-Dec-1997 Shire Pharmaceuticals has announced "excellent" initial trial results for Galantamine, a new drug for Alzheimer's disease. 16-Sep-1997 Shire Pharmaceuticals is acquiring Richwood Pharmaceuticals of Kentucky, the maker of treatments for disorders of the central nervous system, for up to £113m. 05-Aug-1997 Shire Pharmaceuticals is to start trials on Galanthamine as a treatment for Chronic Fatigue Syndrome. 07-May-1997 Shire Pharmaceuticals is acquiring Pharmavene, the US drugs delivery concern, for up to £104m, and will make further acquisitions using funding from a £11.5m planned share offer. 26-Feb-1997 Shire Pharmaceuticals' Alzheimer's disease drug, Reminyl, is moving into the final stage of clinical trials in the US, through its partner Janssen Pharmaceutica. 22-Oct-1996 Shire Pharmaceuticals, the developer of prescription medicines, is in discussions to acquire two or three companies that could market its products. 28-Sep-1996 Shire Pharmaceuticals Group expects to raise £35m from a flotation and will use £20m on development. 26-Jan-1996 Shire Pharmaceuticals Group is to develop and market galanthamine, the Alzheimer's treatment, in a deal with Johnson & Johnson's Belgian operation, Janssen Pharmaceutics. 25-Jan-1996 Shire Pharmaceuticals Group plans to raise about £25m through a flotation. 14-Dec-1995 The information on this page comes from the UK Activity Report. Click here for further details Copyright UK Business Park 1995-2009